Evaluation of the bioavailability of misonidazole (NSC#261037) in capsule and tablet form and pharmacologic effects of daily dosage.
A total of 34 patients were studied in order to evaluate capsule vs. tablet form of misonidazole and intermittent vs. daily administration. These patients were given drug formulation of tablets for one week and capsules for one week on either an intermittent (1, 2, or 3 times per week) or daily schedule. Total doses ranged from 5-15 gm/m2. There was no significant difference seen in mean serum levels or half-lives between capsules and tablets. Daily misonidazole resulted in slight build-up of serum levels in the latter part of the week. There was no difference in toxicities seen with drug daily vs. intermittent administration.
D000328:Adult; D001682:Biological Availability; D002214:Capsules; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006207:Half-Life; D006801:Humans; D008920:Misonidazole / Q000008:administration & dosage / Q000378:metabolism*; D009369:Neoplasms / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000378:metabolism*; D013607:Tablets
D002214:Capsules; D009593:Nitroimidazoles; D013607:Tablets; D008920:Misonidazole